Madelung’s disease is a rare disorder of fat metabolism in which large, symmetrical masses of fatty tissue grow in specific areas of the body, most commonly the neck, shoulders, and upper arms. Also called multiple symmetric lipomatosis, it affects roughly 1 in 25,000 people and can range from a cosmetic concern to a condition that compresses the airway and threatens breathing.
How Fat Deposits Develop and Where They Appear
Unlike ordinary weight gain, Madelung’s disease produces unencapsulated fatty masses that grow symmetrically on both sides of the body. The fat deposits don’t behave like normal fat. They resist diet and exercise, and they tend to infiltrate surrounding muscles, glands, and blood vessels rather than staying neatly separated from other tissues.
The classic presentation, sometimes called a “Madelung collar,” involves large fat masses ringing the neck and extending across the shoulders and upper back. But the disease doesn’t always look that way. Clinicians have identified several patterns of fat distribution:
- Type I: Fat concentrated around the neck, shoulders, and upper arms, creating a “pseudoathletic” appearance in the upper body.
- Type II: Fat distributed around the hips, buttocks, and upper legs, which can look similar to ordinary obesity and often goes undiagnosed.
- Type III: Fat spread more generally across the trunk and limbs, sparing the head, forearms, and lower legs.
On CT and MRI scans, the excess fat looks identical to normal fat in density and signal. What distinguishes it is the pattern: symmetrical, unencapsulated masses that push muscles and glands out of position. In neck imaging, the sternocleidomastoid muscles and salivary glands get displaced forward in a distinctive way radiologists describe as resembling a bird spreading its wings.
Who Gets It and Why
Early studies reported Madelung’s disease almost exclusively in middle-aged men of Mediterranean descent, with a male-to-female ratio as high as 15 to 1. More recent research from central Europe tells a different story. A large German cohort found the ratio was actually 1 male for every 2.5 females, suggesting the condition has been significantly underdiagnosed in women, likely because Type II fat distribution mimics common obesity.
Chronic heavy alcohol use has a strong association with the disease. The exact metabolic link isn’t fully understood, but alcohol appears to contribute to disease development or progression. Importantly, quitting alcohol does not reverse or stop the growth of the fatty masses once they’ve formed. Some evidence suggests that continued drinking may actually stabilize existing deposits, while periods of abstinence can paradoxically coincide with further growth, though this relationship remains unclear.
Genetics also play a role. Family studies point to either autosomal dominant or mitochondrial inheritance patterns. One specific mitochondrial DNA mutation, found in a condition called MERRF syndrome (a rare disorder involving seizures and muscle problems), has been identified in about 16% of Madelung’s disease cases. Some people carry this mutation with lipomatosis as their only symptom, while others develop the full neurological syndrome. This mitochondrial connection suggests the disease may partly stem from defective energy processing in fat cells.
Complications Beyond Appearance
The fatty masses are benign, meaning they’re not cancerous. But “benign” doesn’t mean harmless. As deposits grow over months and years, they can compress critical structures in the neck and chest. Difficulty swallowing, limited neck movement, and neck or throat pain are common complaints. In long-standing cases, fat tissue can push against the trachea and larynx, causing breathing problems that range from mild shortness of breath to severe respiratory distress requiring emergency intervention.
Fat can also extend into the mediastinum, the space in the chest between the lungs. When this happens, the airway compression becomes harder to treat surgically because the tissue wraps around vital structures. One case report describes a patient whose first symptom was severe difficulty breathing, ultimately needing an emergency tracheotomy combined with surgical fat removal.
Metabolic complications are also common. Many patients have elevated triglycerides, insulin resistance, liver enzyme abnormalities, and other markers of disordered fat metabolism, problems that overlap with but are distinct from those caused by alcohol use alone.
Surgical Treatment and Recurrence
Surgery is currently the most common treatment, but it’s considered palliative rather than curative. The two main approaches are lipectomy (open surgical removal) and liposuction, and each has significant tradeoffs.
Lipectomy allows surgeons to see and protect nearby nerves and blood vessels during removal. However, because the fatty masses lack a capsule and infiltrate surrounding tissue, it’s difficult to distinguish diseased fat from healthy fat during the operation. Complications include infection, bleeding, fluid collections, and scarring. Most surgeons recommend a single transverse incision across the neck rather than multiple smaller cuts.
Liposuction is less invasive and leaves smaller scars, but the fatty tissue in Madelung’s disease tends to be dense and fibrous, making it difficult to suction out completely. There’s no reliable way to predict beforehand whether liposuction will work well in a given patient.
The biggest challenge with either approach is recurrence. Roughly 45% to 63% of patients experience regrowth after surgery. The numbers vary by technique: liposuction carries recurrence rates as high as 95%, while lipectomy (alone or combined with liposuction) has recurrence rates around 50%. Complete removal is often impossible when fat has infiltrated around nerves, blood vessels, and other structures, which means close long-term follow-up is essential.
An Emerging Medical Treatment
Because surgery offers only temporary results for many patients, researchers have been searching for a drug-based approach. A small but promising trial tested daily injections of metreleptin, a synthetic version of the hormone leptin, which helps regulate fat storage and metabolism. Four patients received the treatment for 24 weeks.
The results were striking. All patients experienced progressive shrinkage of their fatty masses. In the two younger male patients, the visible lumps disappeared entirely by week 24. Across the group, trunk fat dropped by an average of 38.5%, body weight fell by 13.3%, and waist circumference decreased by nearly 12%. Metabolic markers improved significantly too: triglycerides dropped by nearly 39%, and measures of insulin resistance improved substantially. The treatment was well tolerated, and all patients chose to continue.
This is still early-stage research with only four patients, but it represents the first pharmacological approach to show meaningful results. If confirmed in larger studies, leptin-based therapy could change how the disease is managed, particularly for patients facing repeated surgeries.